PL BioScience Names Ole Henrik Bang-Andreasen as New Board Member

Posted on by

AACHEN, Germany, Oct. 28, 2025 — PL BioScience GmbH, a German life science firm focused on developing and producing Human Platelet Lysate (HPL) for cell expansion and manufacturing, announced today the appointment of Ole Henrik Bang-Andreasen to its board of directors. This appointment follows the recent passing of board member Reinhard Vogt.

Ole Henrik Bang-Andreasen brings substantial transatlantic industry experience, leadership expertise, and capital markets insight to the board. His contributions are expected to be highly valuable as PL BioScience embarks on a new phase of accelerated development, expansion, and enhanced value creation. Currently, he serves as a Principal in the London office of AVANT BIO, a U.S.-based early-stage and growth equity firm, where his focus is on advancing healthcare and biotechnology ventures. Ole earned his Bachelor of Science in Accounting and Finance from Northeastern University in Boston and his Master of Science in Econometrics from Boston University. He also holds board positions at PathPresenter, Wasteless Bio, and HC Andersen Capital, and serves as Chairman of the board at Portunus Solutions.

Hatim Hemeda, CEO of PL BioScience, commented: “Collaborating with Ole during this board seat transition has been a great pleasure. His profound scientific understanding, coupled with sharp investment acumen, has already proven highly beneficial to our team. We eagerly anticipate continuing our work together as PL BioScience further strengthens its position as a leader in Human Platelet Lysate technology. Concurrently, we are deeply saddened by the passing of our colleague, friend, and mentor, Reinhard Vogt.”

Ole Henrik Bang-Andreasen added: “My appointment to the PL BioScience (PLB) board is a bittersweet moment, given the recent loss of my colleague and mentor, Reinhard Vogt. As I take on this role, building upon Reinhard’s legacy, I am keen to help PLB establish itself as the world’s foremost HPL company, beginning with a new facility in Aachen and a demanding yet promising future ahead.”

Remembering Reinhard Vogt

PL BioScience GmbH regretfully announces the passing of Reinhard Vogt on September 8, 2025. Reinhard had served as a cherished friend, mentor, and member of our Board of Directors since 2024.

Revered throughout the life science sector as a visionary, Reinhard’s experience, compassion, and enthusiasm for life sciences deeply influenced all who knew him. We are thankful for his leadership and the moments we shared. Our deepest sympathies are extended to his family and friends during this period.

About PL BioScience:

PL BioScience GmbH, a life science firm based in Aachen, Germany, focuses on the production and advancement of Human Platelet Lysate (HPL). The company has innovated proprietary technology to create entirely artificial HPL, enabling a completely laboratory-generated, scalable source of HPL. PL BioScience currently provides a broad selection of donor-derived, natural HPL products designed for various uses – known as the ELAREM™ platform. ELAREM™ facilitates the smooth transition of regenerative medicine innovations from academic and preclinical research to cell therapy and biopharmaceutical manufacturing, ultimately reaching patients who require them. PL BioScience holds the exclusive global patent for the gamma-irradiation of HPL, which encompasses the manufacturing procedure for ELAREM™ Ultimate-FD PLUS.

For additional details about PL BioScience and the ELAREM™ platform, please visit:

Contact Information:
Dr. Hatim Hemeda, CEO
PL BioScience GmbH
+49(0)24195719-100

Media Relations:
MC Services AG
Raimund Gabriel, Dr. Regina Lutz
+49 (0)89 210 228 0

U.S. Inquiries: Catherine Featherston
+1-203-444-4393
E-Mail: